Minister says Indian pharma sector can grow to 65 bln USD by 2024
Indian minister for chemicals and fertilizers D. V. Sadananda Gowda Thursday said the country was one of the largest manufacturers and exporters of generic medicines across the world.
"Indian pharma sector can grow to 65 billion U.S. dollars industry by 2024," Gowda said. "We have recently launched schemes for the development of seven mega parks-three bulk drug parks and four medical device parks across the country."
"New manufacturers will be eligible for the Production Linked Incentive (PLI) Scheme under which they will be eligible for financial incentives on basis of their sales for the first five to six years."
During the initial phase, he said, Hydroxychloroquine (HCQ) and Azithromycin was identified as one of medicines under treatment protocol for COVID-19 in emergency cases.
The minister said India earned the reputation of reliable suppliers of medicines as it supplied these medicines to more than 120 countries across the world.
Addressing a video conference FICCI LEADS 2020, the minister highlighted that India is one of the largest manufacturers and exporter of generic medicines across the world.
Gowda also said the market size of chemicals and petrochemicals sector in India is around 165 billion U.S. dollars, and the size was expected to grow up to 300 billion U.S. dollars by 2025.
Looking for chemical products? Let suppliers reach out to you!
2026-06-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
Eli Lilly to Appeal UK Rejection of Alzheimer's Drug Kisunla Impacting Thousands of Patients
-
Abbott to Market MSD’s Sitagliptin Brands in India Targeting 20 Percent of Diabetes Market
-
Pfizer Faces 400 Lawsuits Over Depo-Provera Brain Tumor Risk
-
EU Implements 5 Million Euro Restriction on Chinese Medical Devices
-
48 Scientists Rally as CRO Giant Faces 1.8 Billion RMB Dispute and Criminal Allegations
-
Post-holiday Increase in Acetone Market Inventory Volume and the Struggle for a Good Start in China
-
Downstream Demand Steady, Ethyl Acetate Market Weakly Consolidating
-
Sodium Benzoate (E211): Safety, Benzene Risk, and Preservative Uses
-
Supply and Demand Game: Flexible Trends in the Chinese Melamine Market
-
Premium Global Chemical Sourcing Requests (7 - 11 Feb, 2026)